Journal Article

DKFZ-2021-02340

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Serial assessment of measurable residual disease in medulloblastoma liquid biopsies.

Liu, A. P. Y. ; Smith, K. S. ; Kumar, R. ; Paul, L. ; Bihannic, L. ; Lin, T. ; Maass, K. K.DKFZ* ; Pajtler, K. W.DKFZ* ; Chintagumpala, M. ; Su, J. M. ; Bouffet, E. ; Fisher, M. J. ; Gururangan, S. ; Cohn, R. ; Hassall, T. ; Hansford, J. R. ; Klimo, P. ; Boop, F. A. ; Stewart, C. F. ; Harreld, J. H. ; Merchant, T. E. ; Tatevossian, R. G. ; Neale, G. ; Lear, M. ; Klco, J. M. ; Orr, B. A. ; Ellison, D. W. ; Gilbertson, R. J. ; Onar-Thomas, A. ; Gajjar, A. ; Robinson, G. W. ; Northcott, P. A.

2021
Elsevier New York, NY

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/j.ccell.2021.09.012

Abstract: Nearly one-third of children with medulloblastoma, a malignant embryonal tumor of the cerebellum, succumb to their disease. Conventional response monitoring by imaging and cerebrospinal fluid (CSF) cytology remains challenging, and a marker for measurable residual disease (MRD) is lacking. Here, we show the clinical utility of CSF-derived cell-free DNA (cfDNA) as a biomarker of MRD in serial samples collected from children with medulloblastoma (123 patients, 476 samples) enrolled on a prospective trial. Using low-coverage whole-genome sequencing, tumor-associated copy-number variations in CSF-derived cfDNA are investigated as an MRD surrogate. MRD is detected at baseline in 85% and 54% of patients with metastatic and localized disease, respectively. The number of MRD-positive patients declines with therapy, yet those with persistent MRD have significantly higher risk of progression. Importantly, MRD detection precedes radiographic progression in half who relapse. Our findings advocate for the prospective assessment of CSF-derived liquid biopsies in future trials for medulloblastoma.

Keyword(s): biomarkers ; cell-free DNA ; cerebrospinal fluid ; childhood cancer ; liquid biopsy ; measurable residual disease ; medulloblastoma ; microscopic residual disease ; minimal residual disease ; relapse disease

Note: 2021 Nov 8;39(11):1519-1530.e4

---

Contributing Institute(s):

1. B062 Pädiatrische Neuroonkologie (B062)

Research Program(s):

1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2021

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 25 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---